• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Coffey Steven R. S.

    3/18/26 7:18:21 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KZIA alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Coffey Steven R. S.

    (Last)(First)(Middle)
    THREE INTERNATIONAL TOWERS
    LEVEL 24, 300 BARANGAROO AVE

    (Street)
    SYDNEY, NSWAUSTRALIA2000

    (City)(State)(Zip)

    AUSTRALIA

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    KAZIA THERAPEUTICS LTD [ KZIA ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Ordinary Shares16,000D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    American Depositary Share Option (Right to Buy) (1)04/30/2027American Depositary Shares(2)(3)1,000$0.3348D
    American Depositary Share Option (Right to Buy) (4)07/03/2027American Depositary Shares(2)(3)75,000$8D
    American Depositary Shares (3) (3)Ordinary Shares845(3)ISee footnote(5)
    American Depositary Shares (3) (3)Ordinary Shares1,122(3)ISee footnote(6)
    Explanation of Responses:
    1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 30, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on April 30, 2024.
    2. Each ADS option is convertible into ADSs upon exercise.
    3. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.
    4. The ADSs subject to the ADS option vested as to 100% on July 3, 2025. The ADS option was granted on July 3, 2025.
    5. The ADSs are held directly by Coffey Family Investments Pty Limited, of which the Reporting Person is a director. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 3 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
    6. The ADSs are held directly by Fortune 501 Pty Limited. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 3 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ Jeffrey Bonacorda, Attorney-in-Fact03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $KZIA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KZIA

    DatePrice TargetRatingAnalyst
    2/6/2025$3.00Buy
    Maxim Group
    10/14/2021$18.00Buy
    Maxim Group
    More analyst ratings

    $KZIA
    SEC Filings

    View All

    SEC Form F-3 filed by Kazia Therapeutics Limited

    F-3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    3/17/26 9:25:12 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Kazia Therapeutics Limited

    SCHEDULE 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    2/20/26 4:09:37 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    1/27/26 8:25:42 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $KZIA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

    Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models a

    1/30/26 8:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

    SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC). To date, three patients with metastatic TNBC treated with paxalisib-based regimens have demonstrated meaningful clinical responses, including two partial responses (PRs) in trial participants and one confirmed complete metabolic response (CR) in a patient treated under an expanded access program. Clinical Highlights 2 of 2 evaluable patients enrolled in the Phase 1b trial achieved partial responses

    1/27/26 8:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

    SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach. "We are entering JPM Week with strong strategic and clinical momentum," said Dr. John Friend, M.D., Chief Executive Officer of Kazia Therap

    1/8/26 9:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Coffey Steven R. S.

    3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)

    3/18/26 7:18:21 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Friend John E. Ii

    3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)

    3/18/26 6:35:38 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Simpson Jeremy

    3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)

    3/18/26 6:32:35 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Kazia Therapeutics with a new price target

    Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $3.00

    2/6/25 7:53:38 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Kazia Therapeutics with a new price target

    Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $18.00

    10/14/21 8:02:40 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    Leadership Updates

    Live Leadership Updates

    View All

    KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

    SYDNEY, Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia's Board of the Directors (the "Board") as a Non-Executive Director. Mr. Apple brings more than 25 years of senior leadership experience in the pharma industry to Kazia, including 16 years with Antares Pharma, Inc. ("Antares") as Senior Vice President, Chief Financial Officer and Corporate Secretary, and went on to serve as President and Chief Executive Officer

    1/18/24 7:30:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER

    SYDNEY, Dec. 13, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer. In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022. Kazia CEO, Dr. James Garner, commented, "

    12/13/21 11:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

    SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States. Kazia CEO, Dr. James Garner, commented, "We are delighted to welcome John to the Kazia team. With paxalisib moving rapidly towards potential commercialization, and EVT801 now in the clin

    11/15/21 11:00:00 AM ET
    $CLRB
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

    SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    11/14/24 4:19:36 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Kazia Therapeutics Limited

    SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    11/6/24 7:53:45 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

    SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    8/12/24 7:28:02 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care